Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study
- 25 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 15 (4), 539-551
- https://doi.org/10.1007/s11102-011-0365-5
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Effects of Long-acting Release Octreotide on Glucose Homeostasis in Acromegaly Patients after Trans-Sphenoidal SurgeryHormone and Metabolic Research, 2011
- Medical therapy in acromegalyNature Reviews Endocrinology, 2011
- Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicityTrends in Endocrinology & Metabolism, 2010
- Visceral Adiposity IndexDiabetes Care, 2010
- Acromegaly pathogenesis and treatmentJCI Insight, 2009
- Lower Visceral and Subcutaneous but Higher Intermuscular Adipose Tissue Depots in Patients with Growth Hormone and Insulin-Like Growth Factor I Excess Due to AcromegalyJournal of Clinical Endocrinology & Metabolism, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatmentClinical Endocrinology, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Action of Growth Hormone in Adipose TissueHormone Research, 1997